A Phase 2/3 VISTA clinical trial assessing a gene therapy for X-linked retinitis pigmentosa (XLRP) has shown significant improvements in low-light vision.
Read more for FREE in BioNews ⬇️⬇️⬇️
progress.org.uk/gene-therapy...
@pet-bionews.bsky.social
Explore
@pet-bionews.bsky.social